141 related articles for article (PubMed ID: 16570018)
21. Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors.
Zineh I; Luo X; Welder GJ; Debella AE; Wessel TR; Arant CB; Schofield RS; Chegini N
Pharmacotherapy; 2006 Mar; 26(3):333-40. PubMed ID: 16503719
[TBL] [Abstract][Full Text] [Related]
22. Low immunogenicity of endothelial derivatives from rat embryonic stem cell-like cells.
Ladhoff J; Bader M; Brösel S; Effenberger E; Westermann D; Volk HD; Seifert M
Cell Res; 2009 Apr; 19(4):507-18. PubMed ID: 19238174
[TBL] [Abstract][Full Text] [Related]
23. Stimulatory effects of atorvastatin on extracellular nucleotide degradation in human endothelial cells.
Osman L; Amrani M; Isley C; Yacoub MH; Smolenski RT
Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):1125-8. PubMed ID: 17065076
[TBL] [Abstract][Full Text] [Related]
24. Detailed in vivo analysis of interferon-gamma induced major histocompatibility complex expression in the the central nervous system: astrocytes fail to express major histocompatibility complex class I and II molecules.
Horwitz MS; Evans CF; Klier FG; Oldstone MB
Lab Invest; 1999 Feb; 79(2):235-42. PubMed ID: 10068211
[TBL] [Abstract][Full Text] [Related]
25. Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains.
Kuipers HF; Biesta PJ; Groothuis TA; Neefjes JJ; Mommaas AM; van den Elsen PJ
Hum Immunol; 2005 Jun; 66(6):653-65. PubMed ID: 15993711
[TBL] [Abstract][Full Text] [Related]
26. Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line.
Bertrand-Thiebault C; Masson C; Siest G; Batt AM; Visvikis-Siest S
J Cardiovasc Pharmacol; 2007 May; 49(5):306-15. PubMed ID: 17513950
[TBL] [Abstract][Full Text] [Related]
27. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
28. Atorvastatin protects against angiotensin II-induced injury and dysfunction in human umbilical vein endothelial cells through bradykinin 2 receptors.
Zhang XS; Ren JH; Lu JP; Fan Y
J Cardiovasc Pharmacol; 2010 Aug; 56(2):171-6. PubMed ID: 20489655
[TBL] [Abstract][Full Text] [Related]
29. Role of intra-islet endothelial cells in islet allo-immunity.
Bharat A; Saini D; Benshoff N; Goodman J; Desai NM; Chapman WC; Mohanakumar T
Transplantation; 2007 Nov; 84(10):1316-23. PubMed ID: 18049117
[TBL] [Abstract][Full Text] [Related]
30. Immune responsiveness against allogeneic platelet transfusions is determined by the recipient's major histocompatibility complex class II phenotype.
Sayeh E; Aslam R; Speck ER; Le-Tien H; Lazarus AH; Freedman J; Semple JW
Transfusion; 2004 Nov; 44(11):1572-8. PubMed ID: 15504162
[TBL] [Abstract][Full Text] [Related]
31. Class-specific pro-apoptotic effect of statins on human vascular endothelial cells.
Mück AO; Seeger H; Wallwiener D
Z Kardiol; 2004 May; 93(5):398-402. PubMed ID: 15160275
[TBL] [Abstract][Full Text] [Related]
32. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response.
Boodhwani M; Nakai Y; Voisine P; Feng J; Li J; Mieno S; Ramlawi B; Bianchi C; Laham R; Sellke FW
Circulation; 2006 Jul; 114(1 Suppl):I402-8. PubMed ID: 16820608
[TBL] [Abstract][Full Text] [Related]
33. Statins as a newly recognized type of immunomodulator.
Kwak B; Mulhaupt F; Myit S; Mach F
Nat Med; 2000 Dec; 6(12):1399-402. PubMed ID: 11100127
[TBL] [Abstract][Full Text] [Related]
34. Tissue-specific effects of atorvastatin on 3-hydroxy-3-methylglutarylcoenzyme A reductase expression and activity in spontaneously hypertensive rats.
Chen GP; Yao L; Lu X; Li L; Hu SJ
Acta Pharmacol Sin; 2008 Oct; 29(10):1181-6. PubMed ID: 18817622
[TBL] [Abstract][Full Text] [Related]
35. Atorvastatin enhances humoral immune responses but does not alter renal injury in experimental crescentic glomerulonephritis.
Phoon RK; Kitching AR; Jones LK; Holdsworth SR
Nephrology (Carlton); 2009 Oct; 14(7):650-7. PubMed ID: 19796023
[TBL] [Abstract][Full Text] [Related]
36. MHC class II-mediated antigen presentation by alloreactive rat CD4+ T cells does not induce regulatory properties.
Otto C; Heeg A; Kottenmeier S; Tiurbe GC; Thiede A; Ulrichs K
Transplant Proc; 2006 Apr; 38(3):755-6. PubMed ID: 16647463
[TBL] [Abstract][Full Text] [Related]
37. The phytoestrogen biochaninA weakens acute cardiac allograft rejection without affecting the reproductive system.
Schrepfer S; Deuse T; Schäfer H; Koch-Nolte F; Braendle W; Reichenspurner H
Transpl Immunol; 2005 Oct; 15(1):45-53. PubMed ID: 16223672
[TBL] [Abstract][Full Text] [Related]
38. Systemic evaluation of gene expression changes in major target organs induced by atorvastatin.
Kato N; Liang YQ; Ochiai Y; Jesmin S
Eur J Pharmacol; 2008 Apr; 584(2-3):376-89. PubMed ID: 18295756
[TBL] [Abstract][Full Text] [Related]
39. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins.
Smith C; Halvorsen B; Otterdal K; Waehre T; Yndestad A; Fevang B; Sandberg WJ; Breland UM; Frøland SS; Oie E; Gullestad L; Damås JK; Aukrust P
Cardiovasc Res; 2008 Jul; 79(1):195-203. PubMed ID: 18339644
[TBL] [Abstract][Full Text] [Related]
40. Beta4 integrin is involved in statin-induced endothelial cell death.
Feng C; Ye C; Liu X; Ma H; Li M
Biochem Biophys Res Commun; 2004 Oct; 323(3):858-64. PubMed ID: 15381079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
